Gubra A/S (GUBRF)

Market Cap	1.02B -30.6%
Revenue (ttm)	415.19M +1,078.3%
Net Income	274.95M
EPS	17.04
Shares Out	n/a
PE Ratio	3.71
Forward PE	11.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	700
Average Volume	328
Open	60.15
Previous Close	98.69
Day's Range	60.15 - 60.15
52-Week Range	60.15 - 102.41
Beta	n/a
RSI	n/a
Earnings Date	Feb 27, 2026

About Gubra

Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, biomarker assays, bioi...

• Industry: Commercial Physical and Biological Research
• Founded: 2008
• Employees: 275
• Stock Exchange: OTCMKTS
• Ticker Symbol: GUBRF

Financial Performance

In 2024, Gubra's revenue was 265.74 million, an increase of 29.63% compared to the previous year's 205.01 million. Losses were -36.50 million, -18.03% less than in 2023.

Financial numbers in DKK